Actinogen Limited, a biotechnology company focused on the treatment of Alzheimer’s Disease and mild cognitive impairment, a transitional stage of cognitive impairment between normal aging and the more serious conditions of Alzheimer’s and dementia, recently announced that it has received approval for the third and final stage of the second…
The U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application submitted by Stemedica Cell Technologies, Inc. The approval means that the company is allowed to initiate a phase 2a clinical study to evaluate the use of an allogeneic stem-cell therapy for…
Phoenix-based Banner Alzheimer’s Institute (BAI) was recently awarded a joint $10 million research funding grant from the Alzheimer’s Association, GHR Foundation and Fidelity Biosciences Research Initiative. The three organizations announced their plan to fund BAI’s efforts, given the organization’s reputation as an internationally recognized Alzheimer’s care and…
In a recent report published by Alzheimer’s Disease International (ADI), titled “Women and Dementia: A global research overview,” researchers reported on key findings regarding the main topics affecting women in relation to dementia from an international viewpoint. In the report, the ADI examined the gender effect in women living with dementia; women caring for people with dementia in a professional caring role; and…
In a recent study published in the Journal of Bodywork and Movement Therapies, researchers at Teesside University in the UK found that combining cognitive activities and elements of yoga, tai chi, qigong and meditation with routine physical exercise improves the quality of life of patients with dementia.
In a recent study published in the journal Behavioural Brain Research, researchers found that Cerebral dopamine neurotrophic factor (CDNF) can improve long-term memory in a mouse model of Alzheimer’s disease. Evidence has pointed to an important role of altered neurotrophic factor signaling in a wide array of…
Burlingame, California based mobile platform company Fanfare Entertainment has partnered with Muses Labs to help develop, optimize, and market a next-generation personalized combination therapy for treatment and prevention of Alzheimer’s disease. The MEND (metabolic enhancement for neurodegeneration) Protocol is designed to enable Alzheimer’s disease patients, their caregivers, family members, and…
A new drug developed at Lancaster University in the United Kingdom that might help to prevent early stages of Alzheimer’s disease and is about to enter clinical trials. The number of individuals affected by dementia is constantly increasing. According to estimates, there are 850,000 cases in the United Kingdom currently, with estimates that the number…
In a recent study published in the open access Nature Publishing Group journal Scientific Reports, Sussex Neuroscience researchers found a direct association between the main culprit of Alzheimer’s disease and memory loss. Alzheimer’s disease is caused by the formation and accumulation of amyloid plaques in…
Investigators at the Blancette Rockefeller Neurosciences Institute (BRNI) recently discovered that the most significant genetic risk factor associated with Alzheimer’s disease, the Apolipoprotein E4 (ApoE4) gene, leads to a decrease in brain synapses, which occurs frequently prior to the onset of amyloid plaques or tangles developing in Alzheimer’s patients. This discovery may alter the…
Get regular updates to your inbox.